✦ LIBER ✦

Disclosure of competing financial interests and role of sponsors in phase III cancer trials

✍ Scribed by Jean–Jacques Tuech; Grégoire Moutel; Patrick Pessaux; Véronique Thoma; Simon Schraub; Christian Herve

Book ID: 116428474
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 90 KB
Volume: 41
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2004.12.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disclosure of Funding Sources and Confli

Disclosure of Funding Sources and Conflicts of Interest in Phase III Surgical Trials: Survey of Ten General Surgery Journals

✍ Bridoux, Valérie; Moutel, Grégoire; Schwarz, Lilian; Michot, Francis; Herve, Chr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 217 KB

Disclosure of Funding Sources and Confli

Disclosure of Funding Sources and Conflicts of Interest in Phase III Surgical Trials: Survey of 10 General Surgery Journals

✍ Sarr, Michael G.; Warshaw, Andrew L. 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 120 KB

The prevalence and influence of self-rep

The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials

✍ Tatiana Goberstein Lerner; Michele da Costa Miranda; Andrea Thaumaturgo Lera; Al 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 142 KB

A phase III trial of neoadjuvant chemoth

A phase III trial of neoadjuvant chemotherapy in head and neck cancer

✍ Paccagnella, A.; Zorat, P.L.; Orlando, A.; Marchiori, C.; Chiarion-Sileni, V.; J 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Induction chemotherapy in head and neck

Induction chemotherapy in head and neck cancer: Results of a phase III trial

✍ Dr. Jean-Jacques Mazeron; Michel Martin; Bernard Brun; Laval Grimard; Gilles Lel 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

stage 11-Ill-IV squamous cell carcinoma of the oropharynx or oral cavity were randomized to induction chemotherapy, consisting of bleomycin (10 mg/m\*/day in continuous infusion from day 1 to day 5), methotrexate (120 mg/m2 on day 2) followed by folink acid, 5-fluorouracil (5 FU) (600 mg/m2 on day 2

Randomized Phase III Trial of Postoperat

Randomized Phase III Trial of Postoperative Radiochemotherapy ± Amifostine in Head and Neck Cancer

✍ Peter Vacha,Fabian Fehlauer,Birgit Mahlmann… 📂 Article 📅 2003 🏛 Springer 🌐 German ⚖ 94 KB